DRFS
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Federico Rojo, Clive R Taylor, Carlos Barrios, Laura Torrecillas, Manuel Ruiz-Borrego, Sandra Perez-Buira, Jose Bines, Angel Guerrero-Zotano, Jose A Garcia-Saenz, Roberto Torres, Juan de la Haba-Rodriguez, Francisco Ayala, Henry Gomez, Antonio Llombart, Maria Rodriguez de la Borbolla, Jose Manuel Baena-Cañada, Agusti Barnadas, Lourdes Calvo, Jesus Herranz, Raul Rincon, Rosalia Caballero, Begoña Bermejo, Partha S Ray, Miguel Martin, GEICAM_CIBOMA Clinical Trial Group
Clin Cancer Res 31(17) 3715-3724
PURPOSE: In a prespecified GEICAM_CIBOMA trial (NCT00130533) correlative analysis, PAM50 non-basal-like breast cancer (non-BLBC) status distinguished patients with triple-negative breast cancer (TNBC) who are most likely to benefit from adjuvant capecitabine. The standardized forkhead box C1 (FOXC1) IHC test has demonstrated strong reliability in classifying the BLBC subtype throughout TNBC cohorts. This translational analysis aimed to evaluate the prognostic/predictive significance of BLBC classification by FOXC1 IHC in the phase III GEICAM_CIBOMA clinical trial. EXPERIMENTAL DESIGN: Tumor tissues from patients with TNBC randomized to standard (neo)adjuvant chemotherapy followed by capecitabine versus observation were analyzed using the standardized FOXC1 IHC test to assess its BLBC/non-BLBC TNBC subtyping capacity as a distant relapse-free survival clinical outcome predictor of capecitabine benefit (exploratory endpoints: disease-free survival, overall survival, and recurrence-free survival). RESULTS: A total of 705 (80.5%) patients from the GEICAM_CIBOMA trial were evaluable for FOXC1 expression analysis, with balanced distribution between the trial's treatments. FOXC1 proportion/intensity (VFOXC1) score-based subtyping demonstrated a strong association [AUC = 0.87; 95% confidence interval (CI), 0.84-0.91] and agreement (κ index = 0.43; P < 0.0001) with PAM50 molecular subtyping. VFOXC1 non-BLBC TNBC subtype was a significant independent predictor of clinical benefit with capecitabine for distant relapse-free survival (HR, 0.44; 95% CI, 0.25-0.76; P = 0.003). This predictive effect of VFOXC1 non-BLBC on capecitabine efficacy was further confirmed at disease-free survival (HR, 0.47; 95% CI, 0.28-0.78; P = 0.003), overall survival (HR, 0.48; 95% CI, 0.24-0.96; P = 0.038), and recurrence-free survival (HR, 0.39; 95% CI, 0.22-0.72; P = 0.002). CONCLUSIONS: This ambispective GEICAM_CIBOMA translational analysis validated FOXC1-based basal-like/non-basal-like subtyping as a pragmatic alternative to PAM50 subtyping and independently predicted the benefit of adding capecitabine to standard (neo)adjuvant chemotherapy in TNBC.
1 个 Figure · 2 个 KM 面板
Figure 2. Survival analyses showing the primary endpoint of DRFS for patients randomly assigned to the capecitabine or observation arm in the GEICAM_CIBOMA translational study cohort. A, FOXC1 IHC detection by the standardized FOXC1 IHC test, showing positive (right image) and negative (left image) staining in two representative TNBC tumor samples from the GEICAM_CIBOMA trial cohort. The line shows 30 µm. Magnification, ×200. B and C, Kaplan–Meier curves for VFOXC1.
这些图片未产生 KM 曲线结果,不在主页面重复展示。